N Engl J Med. 2024 Jan 11;390(2):118-131. BACKGROUNDThe early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for thetreatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumoractivity, but resis…

<BACKGROUND>Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared </background>…

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial ARTICLES| VOLUME 401, ISSUE 10378, P733-746, MARCH 04, 2023 THE LANCET Summary <Background>Sotorasib is a spec</background>…